Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo ...

Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. As the U.S. market experiences heightened volatility ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright & Co. on April 4, 2025. The analyst firm set a price target for $7.50 expecting AKBA to rise to within ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Xoanacyl as a treatment for high phosphate levels ...

The rose has a reputation as a garden princess, requiring pampering before it will put on its show of dainty petals and sweet perfume. Some roses require regular spraying and fertilizing to look their ...